Citations

Clear

34 citation(s) found for "Schenk, Ed".

Abstract A123: CD14+ monocyte recruitment, transformation and support of tumor survival in a lung cancer model
Dietz, Allan B. , Schenk, Erin L. , Dietz, Allan B

Mayo Clinic

Cancer Immunology Research | May 20, 2016 | Volume: 4 | Issue: 1_Supplement | Pages: A123-A123

10.1158/2326-6074.cricimteatiaacr15-a123 Get It

Abstract Our previous work has shown that in multiple hematologic and solid malignancies, an increased presence of CD14+HLA-DRlo/neg cells in the peripheral blood are associated with systemic immune suppression and poor prognosis. We have also demonstrated that glioblastoma and non-Hodgkin lymphoma tumor cells can convert healthy donor CD14+ cells into CD14+HLA-DRlo/neg. Thus, a critical step toward the generation of these immune suppressive cells is the recruitment of CD14+ monocytes to the tumor. In this study we investigated the mechanism for monocyte recruitment by lung cancer cell lines, the effect these lines have on the monocytes, and the effect the monocytes have on the tumor. Monocyte recruitment by H23, a human lung adenocarcinoma cell line, was studied using freshly isolated CD14+ cells and measured in real time with live cell imaging. Monocytes from 10 of 10 unique healthy donors robustly migrated towards H23 supernatant in a dose dependent fashion. H23 produces CCL2 at levels of 9160 ± 1615 pg/mL measured by ELISA in addition to elaborating the monocyte recruitment factors CXCL1 and IL-8 seen by cytokine array. A 2 day co-culture of H23 with monocytes from 17 of 18 unique healthy volunteers resulted in downregulated monocyte cell surface expression of HLA-DR by 49.7% ± 22.1%, a phenotype known to mediate both local and systemic immune suppression. Most importantly, monocytes had a positive effect on H23 survival under stress conditions. H23 continuously exposed to cisplatin in culture had improved survival when co-cultured with monocytes for 2 days prior to cisplatin exposure. After 6 days of low serum growth conditions, H23 survival and proliferation was bolstered by the presence of monocytes in culture resulting in a 2 fold greater number of viable H23 cells compared to H23 cultured in low serum without monocytes. These experiments have been repeated and showed that 3 of 4 additional human lung cancer cell lines demonstrated improved survival in low serum growth conditions when co-cultured with monocytes. In conclusion, we have demonstrated the active recruitment of monocytes by lung cancer cell lines, the transformation of the monocytes to an immune suppressive phenotype and the monocyte cancer cross-talk that results in improved tumor survival when exposed to the likely in vivo conditions of a nutrient poor environment or chemotherapy. Taken together these results suggest that the recruitment of monocytes may confer additional survival benefit in the tumor microenvironment beyond local immune suppression and angiogenesis. Citation Format: Erin Schenk, Allan Dietz. CD14+ monocyte recruitment, transformation and support of tumor survival in a lung cancer model. [abstract]. In: Proceedings of the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival; September 16-19, 2015; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2016;4(1 Suppl):Abstract nr A123.
First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction
Landau, Heather , Comenzo, Raymond L. , Seldin, David C. , Weiss, Brendan M. , Zonder, Jeffrey A. , Merlini, Giampaolo , Schönland, Stefan , Walling, Jackie , Kinney, Gene G. , Koller, Martin, Schenk, Dale B., Guthrie, Spencer , Liedtke, Michaela , Seldin, David, Weiss, Brendan, Zonder, Jeffrey, Guthrie, Spencer D, Gertz, Morie A. , Merlini, Giampaolo , Schönland, Stefan

Mayo Clinic

Journal of Clinical Oncology | February 8, 2016 | Volume: 34 | Issue: 10 | Pages: 1097-1103

10.1200/jco.2015.63.6530 | PMID 26858336 Get It

Purpose Light chain (AL) amyloidosis is caused by the accumulation of misfolded proteins, which induces the dysfunction of vital organs. NEOD001 is a monoclonal antibody targeting these misfolded proteins. We report interim data from a phase I/II dose-escalation/expansion study of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction (NCT01707264). Patients and Methods Patients who had completed at least one previous anti–plasma cell-directed therapy, had partial hematologic response or better, and had persistent organ dysfunction received NEOD001 intravenously every 28 days. Dose levels of 0.5, 1, 2, 4, 8, 16, and 24 mg/kg were evaluated (3 + 3 study design). Primary objectives were to determine the maximum tolerated dose and the recommended dose for future studies and to evaluate safety/tolerability. Secondary and exploratory objectives included pharmacokinetics, immunogenicity, and organ responses on the basis of published consensus criteria. Results Twenty-seven patients were enrolled in seven cohorts (dose-escalation component). No drug-related serious adverse events (AEs), discontinuations because of drug-related AEs, dose-limiting toxicities, or antidrug antibodies were reported. The most frequent AEs were fatigue, upper respiratory tract infection, cough, and dyspnea. Recommended dosing was 24 mg/kg. Pharmacokinetics support intravenous dosing every 28 days. Of 14 cardiac-evaluable patients, eight (57%) met the criteria for cardiac response and six (43%) had stable disease. Of 15 renal-evaluable patients, nine (60%) met the criteria for renal response and six (40%) had stable disease. Conclusion Monthly infusions of NEOD001 were safe and well tolerated. Recommended future dosing was 24 mg/kg. Organ response rates compared favorably with those reported previously for chemotherapy. A phase II expansion is ongoing. A global phase III study (NCT02312206) has been initiated. Antibody therapy targeting misfolded proteins is a potential new therapy for the management of AL amyloidosis.
Reprogrammed FoxP3+ T Regulatory Cells Become IL-17+ Antigen-Specific Autoimmune Effectors In Vitro and In Vivo
Radhakrishnan, Suresh , Cabrera, Rosalyn, Schenk, Erin L. , Nava-Parada, Pilar , Bell, Michael P., Keulen, Virginia P. Van , Marler, Ronald J., Felts, Sara J. , Pease, Larry R.

Mayo Clinic

The Journal of Immunology | April 18, 2014 | Volume: 181 | Issue: 5 | Pages: 3137-3147

10.4049/jimmunol.181.5.3137 | PMID 18713984 Get It

Abstract Lymphocyte differentiation from naive CD4+ T cells into mature Th1, Th2, Th17, or T regulatory cell (Treg) phenotypes has been considered end stage in character. In this study, we demonstrate that dendritic cells (DCs) activated with a novel immune modulator B7-DC XAb (DCXAb) can reprogram Tregs into T effector cells. Down-regulation of FoxP3 expression after either in vitro or in vivo Treg-DCXAb interaction is Ag-specific, IL-6-dependent, and results in the functional reprogramming of the mature T cell phenotype. The reprogrammed Tregs cease to express IL-10 and TGFβ, fail to suppress T cell responses, and gain the ability to produce IFN-γ, IL-17, and TNF-α. The ability of IL-6+ DCXAb and the inability of IL-6−/− DCXAb vaccines to protect animals from lethal melanoma suggest that exogenously modulated DC can reprogram host Tregs. In support of this hypothesis and as a test for Ag specificity, transfer of DCXAb into RIP-OVA mice causes a break in immune tolerance, inducing diabetes. Conversely, adoptive transfer of reprogrammed Tregs but not similarly treated CD25− T cells into naive RIP-OVA mice is also sufficient to cause autoimmune diabetes. Yet, treatment of normal mice with B7-DC XAb fails to elicit generalized autoimmunity. The finding that mature Tregs can be reprogrammed into competent effector cells provides new insights into the plasticity of T cell lineage, underscores the importance of DC-T cell interaction in balancing immunity with tolerance, points to Tregs as a reservoir of autoimmune effectors, and defines a new approach for breaking tolerance to self Ags as a strategy for cancer immunotherapy.
Validation of the Prague C&M classification of Barrett's esophagus in clinical practice
Herrero, Lorenza Alvarez, Curvers, Wouter L., Vilsteren, Frederike van, Wolfsen, Herbert C. , Ragunath, Krish , Song, Louis–Michel Wong Kee, Mallant–Hent, Rosalie C., Oijen, Arnoud van, Scholten, Pieter, Schoon, Erik J. , Schenk, Ed, Weusten, Bas L. , Bergman, Jacques

Mayo Clinic

Endoscopy | October 28, 2013 | Volume: 45 | Issue: 11 | Pages: 876-882

10.1055/s-0033-1344952 | PMID 24165812 Get It

Advancing Alzheimer's disease diagnosis, treatment, and care: Recommendations from the Ware Invitational Summit
Naylor, Mary D. , Karlawish, Jason , Arnold, Steven E. , Khachaturian, Ara S. , Khachaturian, Zaven S., Baumgart, Matthew, Banerjee, Sube , Beck, Cornelia, Blennow, Kaj , Brookmeyer, Ron , Brunden, Kurt R. , Buckwalter, Kathleen C., Comer, Meryl, Covinsky, Kenneth E. , Feinberg, Lynn Friss, Frisoni, Giovanni B. , Guimarães, Renato Maia, Gwyther, Lisa P., Hutton, Michael , Kawas, Claudia H. , Kent, David M. , Kuller, Lewis H. , Langa, Kenneth M. , Mahley, Robert W. , Maslow, Katie, Masters, Colin L. , Meier, Diane E. , Neumann, Peter J. , Paul, Steven M., Petersen, Ronald C. , Sager, Mark A., Sano, Mary , Schenk, Dale, Soares, Holly , Stahl, Sidney M., Stern, Yaakov , Weir, David R. , Trojanowski, John Q. , Frisoni, Giovanni B. , Lee, Virginia M.‐Y. , Green, Colin Richard , Hefti, Franz F. , Sperling, Reisa Anne , Deerlin, Vivianna M. Van , Wolk, David A. , Stern, Yaakov , Masters, Colin L , Kent, David M

Mayo Clinic

Alzheimer's & Dementia | September 7, 2012 | Volume: 8 | Issue: 5 | Pages: 445-452

10.1016/j.jalz.2012.08.001 | PMID 22959699 Get It

AbstractTo address the pending public health crisis due to Alzheimer's disease (AD) and related neurodegenerative disorders, the Marian S. Ware Alzheimer Program at the University of Pennsylvania held a meeting entitled “State of the Science Conference on the Advancement of Alzheimer's Diagnosis, Treatment and Care,” on June 21‐22, 2012. The meeting comprised four workgroups focusing on Biomarkers; Clinical Care and Health Services Research; Drug Development; and Health Economics, Policy, and Ethics. The workgroups shared, discussed, and compiled an integrated set of priorities, recommendations, and action plans, which are presented in this article.
Effects of Selective Checkpoint Kinase 1 Inhibition on Cytarabine Cytotoxicity in Acute Myelogenous Leukemia Cells In Vitro
Schenk, Erin L. , Koh, Brian D. , Flatten, Karen S., Peterson, Kevin L. , Hess, Allan D., Karp, Judith E. , Karnitz, Larry M., Parry, David , Smith, B. Douglas , Kaufmann, Scott H.

Mayo Clinic

Clinical Cancer Research | August 6, 2012 | Volume: 18 | Issue: 19 | Pages: 5364-5373

10.1158/1078-0432.ccr-12-0961 | PMID 22869869 Get It

Abstract Purpose: Previous studies have shown that the replication checkpoint, which involves the kinases ataxia telangiectasia mutated and Rad3 related (ATR) and Chk1, contributes to cytarabine resistance in cell lines. In the present study, we examined whether this checkpoint is activated in clinical acute myelogenous leukemia (AML) during cytarabine infusion in vivo and then assessed the impact of combining cytarabine with the recently described Chk1 inhibitor SCH 900776 in vitro. Experimental design: AML marrow aspirates harvested before and during cytarabine infusion were examined by immunoblotting. Human AML lines treated with cytarabine in the absence or presence of SCH 900776 were assayed for checkpoint activation by immunoblotting, nucleotide incorporation into DNA, and flow cytometry. Long-term effects in AML lines, clinical AML isolates, and normal myeloid progenitors were assayed using clonogenic assays. Results: Immunoblotting revealed increased Chk1 phosphorylation, a marker of checkpoint activation, in more than half of Chk1-containing AMLs after 48 hours of cytarabine infusion. In human AML lines, SCH 900776 not only disrupted cytarabine-induced Chk1 activation and S-phase arrest but also markedly increased cytarabine-induced apoptosis. Clonogenic assays demonstrated that SCH 900776 enhanced the antiproliferative effects of cytarabine in AML cell lines and clinical AML samples at concentrations that had negligible impact on normal myeloid progenitors. Conclusions: These results not only provide evidence for cytarabine-induced S-phase checkpoint activation in AML in the clinical setting, but also show that a selective Chk1 inhibitor can overcome the S-phase checkpoint and enhance the cytotoxicity of cytarabine. Accordingly, further investigation of the cytarabine/SCH 900776 combination in AML appears warranted. Clin Cancer Res; 18(19); 5364–73. ©2012 AACR.
Revision of the criteria for Alzheimer's disease: A symposium
DeKosky, Steven T. , Phelps, Creighton H., Petersen, Ronald C. , Frank, Richard , Schenk, Dale, Masterman, Donna, Siemers, Eric , Cedarbaum, Jesse M. , Morimoto, Bruce H., Khachaturian, Ara S. , Mohs, Richard C. , Carrillo, María C. , Knopman, David S. , Gold, Michael , Miller, David S.

Mayo Clinic

Alzheimer's & Dementia | February 2, 2011 | Volume: 7 | Issue: 1 | Pages: No page available

10.1016/j.jalz.2010.12.007 | PMID 21322828 Get It

The current criteria for classification of Alzheimer's disease (AD) have deficiencies that limit drug development, research, and practice. The current standard for the clinical diagnosis of AD, the National Institute of Neurological and Communicative Disorders and Stroke (now known as the National Institute of Neurological Disorders and Stroke), and the Alzheimer's Disease and Related Disorders Association (now known as the Alzheimer's Association) criteria, are nearly 25 years old and have not been revised to incorporate advances in the epidemiology and genetics of AD, studies of clinicopathologic correlations and recent studies of potential diagnostic biomarkers. In a very real sense our ability to diagnose AD with a very high level of certainty has outpaced our current diagnostic criteria. The Alzheimer's Association Research Roundtable convened a meeting in April 2009 to discuss new data and technologies that could, with further development, enable improvements in the clinical diagnosis of AD, especially in its earliest and mildest stages. This meeting reviewed the current standards for detecting and defining the clinical presentation of AD and discussed areas that could contribute to earlier and more accurate definitive clinical diagnosis. These included clinical, neuropsychological, and other performance‐based assessments, genetic contributions, and biochemical and neuroimaging biomarkers that could reflect AD pathology and lead to better ascertainment of AD, mild cognitive impairment, and presymptomatic AD.
A Case–Control Study of Occupational Exposure to Trichloroethylene and Non-Hodgkin Lymphoma
Purdue, Mark P. , Bakke, Berit, Stewart, Patricia A. , Roos, Anneclaire J. De , Schenk, Maryjean, Lynch, Charles F. , Morton, Lindsay M. , Cerhan, James R. , Severson, Richard K., Rothman, Nathaniel , Hartge, Patricia, Colt, Joanne S., Bernstein, Leslie , Cozen, Wendy , Davis, Scott , Cerhan, James R , Morton, Lindsay M , De Roos, Anneclaire J

Mayo Clinic

Environmental Health Perspectives | November 2, 2010 | Volume: 119 | Issue: 2 | Pages: 232-238

10.1289/ehp.1002106 | PMID 21370516 Get It

Abstract Background Previous epidemiologic findings suggest an association between exposure to trichloroethylene (TCE), a chlorinated solvent primarily used for vapor degreasing of metal parts, and non-Hodgkin lymphoma (NHL). Objectives We investigated the association between occupational TCE exposure and NHL within a population-based case–control study using detailed exposure assessment methods. Methods Cases (n = 1,189; 76% participation rate) and controls (n = 982; 52% participation rate) provided information on their occupational histories and, for selected occupations, on possible workplace exposure to TCE using job-specific interview modules. An industrial hygienist assessed potential TCE exposure based on this information and a review of the TCE industrial hygiene literature. We computed odds ratios (ORs) and 95% confidence intervals (CIs) relating NHL and different metrics of estimated TCE exposure, categorized using tertiles among exposed controls, with unexposed subjects as the reference group. Results We observed associations with NHL for the highest tertiles of estimated average weekly exposure (23 exposed cases; OR = 2.5; 95% CI, 1.1–6.1) and cumulative exposure (24 exposed cases; OR = 2.3; 95% CI, 1.0–5.0) to TCE. Tests for trend with these metrics surpassed or approached statistical significance (p-value for trend = 0.02 and 0.08, respectively); however, we did not observe dose–response relationships across the exposure levels. Overall, neither duration nor intensity of exposure was associated with NHL, although we observed an association with the lowest tertile of exposure duration (OR = 2.1; 95% CI, 1.0–4.7). Conclusions Our findings offer additional support for an association between high levels of exposure to TCE and increased risk of NHL. However, we cannot rule out the possibility of confounding from other chlorinated solvents used for vapor degreasing and note that our exposure assessment methods have not been validated.
Retraction: Reprogrammed FoxP3+ T Regulatory Cells Become IL-17+ Antigen-Specific Autoimmune Effectors In Vitro and In Vivo
Cabrera, Rosalyn, Schenk, Erin L. , Nava-Parada, Pilar , Bell, Michael P., Keulen, Virginia P. Van , Marler, Ronald J., Felts, Sara J. , Pease, Larry R.

Mayo Clinic

The Journal of Immunology | May 18, 2010 | Volume: 184 | Issue: 11 | Pages: 6556-6556

10.4049/jimmunol.1090035 | PMID 20483796 Get It

Genetic variation in caspase genes and risk of non-Hodgkin lymphoma: a pooled analysis of 3 population-based case-control studies
Lan, Qing , Morton, Lindsay M. , Hartge, Patricia, Menashe, Idan , Zheng, Tongzhang, Purdue, Mark P. , Cerhan, James R. , Grulich, Andrew E. , Holford, Theodore R. , Vajdic, Claire M. , Leaderer, Brian P., Kricker, Anne , Schenk, Maryjean, Zahm, Shelia Hoar , Chatterjee, Nilanjan , Rothman, Nathaniel , Wang, Sophia , Armstrong, Bruce K. , Zhang, Yawei , Cozen, Wendy , Yeager, Meredith , Davis, Scott , Chanock, Stephen Jacob , Cerhan, James R , Vajdic, Claire M , Morton, Lindsay M , Wang, Sophia S

Mayo Clinic

Blood | May 4, 2009 | Volume: 114 | Issue: 2 | Pages: 264-267

10.1182/blood-2009-01-198697 | PMID 19414860 Get It

Abstract Caspases play a critical role in regulation of apoptosis, cell differentiation, inflammation, and innate immunity, and several are mutated or have altered expression in non-Hodgkin lymphoma (NHL). To study the impact of genetic variation in caspases on NHL risk, we analyzed tag single nucleotide polymorphisms (SNPs) in 12 caspase and related genes in 3 population-based case-control studies (1946 cases and 1808 controls). Gene-based analysis, adjusting for the number of tagSNPs genotyped in each gene, showed significant associations for CASP8, CASP9, and CASP1. SNP-based analysis showed that CASP8 rs6736233 (odds ratio (OR) CG = 1.21; ORCC = 2.13; P trend = .011); CASP9 rs4661636 (ORCT = 0.89; ORTT = 0.77; P trend = .011); and CASP1 rs1785882 (ORAT = 1.12; ORAA = 1.30; P trend = .0054) were significantly associated with NHL risk and consistent across studies. It is noteworthy that genetic variants in CASP8 were associated with risk of all major NHL subtypes. Our findings suggest that genetic variation in caspases may play an important role in lymphomagenesis.